Cargando…

Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality

In 2018, the US Food and Drug Administration (FDA) limited the indication for immune checkpoint inhibitors (ICI) in metastatic bladder cancer to patients with programmed cell death protein ligand-1 (PD-L1)–positive tumors. The impact of the label change on survival outcomes remains unknown. We condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vader, Daniel T, Parikh, Ravi B, Li, Haojie, Imai, Kentaro, Hubbard, Rebecca A, Mamtani, Ronac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364375/
https://www.ncbi.nlm.nih.gov/pubmed/35809072
http://dx.doi.org/10.1093/jncics/pkac050